In cases where obtaining a tissue biopsy is difficult, comprehensive tumor profiling via liquid biopsy is a valuable tool for diagnosing and monitoring cancer. Standard tissue sampling is an invasive procedure which is not always available and does not always yield sufficient sample for testing. Circulating tumor DNA (ctDNA) analysis only requires a simple blood draw and provides results that can be used to help develop treatment and management plans in alignment with precise biomarker results.
This test is an option for patients with hard-to-biopsy tumors, tumors resected at a previous point in time, or metastasized tumors.
This test has Medicare coverage (MolDx approved).